Published in:
01-10-2019 | Pleural Mesothelioma | PLEURAL DISEASE
Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma
Published in: Lung | Issue 5/2019
Login to get accessAbstract
Purpose
Malignant pleural mesothelioma (MPM) is a highly lethal cancer caused by exposure to asbestos. Currently, the diagnosis is a challenge, carried out by means of invasive methods of limited sensitivity. This is a case–control study to evaluate the individual and combined performance of minimally invasive biomarkers for the diagnosis of MPM.
Method
A study of 166 incident cases of MPM and 378 population controls of Mestizo-Mexican ethnicity was conducted. Mesothelin, calretinin, and megakaryocyte potentiating factor (MPF) were quantified in plasma by ELISA. The samples were collected from 2011 to 2016.
Results
Based on ROC analysis and a preset specificity of 95%, the combination of the three biomarkers reached an AUC of 0.944 and a sensitivity of 82% in men. In women, an AUC of 0.937 and a sensitivity of 87% were reached. In nonconditional logistic regression models, the adjusted ORs in men were 7.92 (95% CI 3.02–20.78) for mesothelin, 20.44 (95% CI 8.90–46.94) for calretinin, and 4.37 (95% CI 1.60–11.94) for MPF. The ORs for women were 28.89 (95% CI 7.32–113.99), 17.89 (95% CI 3.93–81.49), and 2.77 (95% CI 0.47–16.21), respectively.
Conclusions
To our knowledge, this is the first study evaluating a combination of mesothelin, calretinin, and MPF, and demonstrating a sex effect for calretinin. The biomarker panel showed a good performance in a Mestizo-Mexican population, with high sensitivity and specificity for the diagnosis of MPM.